EVER SUPREME BIO TECHNOLOGY CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2016-12-01
- Employees
- -
- Market Cap
- -
A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: HLA-G-CAR.BiTE allogeneic γδ T cells
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06150885
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
Phase 2
Recruiting
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- Other: Control group
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT06147986
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Phase 1
Recruiting
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: Control groupBiological: Allogeneic umbilical cord mesenchymal stem cells
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT05532943
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
Phase 1
Active, not recruiting
- Conditions
- COVID-19 Infection
- Interventions
- Biological: Allogeneic umbilical cord mesenchymal stem cellsBiological: Controlled normal saline
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05501418
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04434768
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
Phase 2
- Conditions
- GBM
- Interventions
- Biological: autologous dendritic cells
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04115761
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Non-US, Taiwan
🇨🇳Chang-Gung Memorial Hospital at Lin-Ko, Taoyuan, Non-US, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction
Phase 1
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Ever Supreme Bio Technology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT04056819
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Non-US, Taiwan
© Copyright 2025. All Rights Reserved by MedPath